期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 34, 期 3, 页码 691-700出版社
IOS PRESS
DOI: 10.3233/JAD-122143
关键词
Alzheimer's disease; amyloid-beta protein precursor; cholinergic neurons; endocytosis; endosomes; septal nuclei
资金
- Alzheimer's Association [IIRG-07-60047]
- National Institutes of Health [5P01AG017617, 5F31AG029787]
Early endosomal changes, a prominent pathology in neurons early in Alzheimer's disease, also occur in neurons and peripheral tissues in Down syndrome. While in Down syndrome models increased amyloid-beta protein precursor (A beta PP) expression is known to be a necessary contributor on the trisomic background to this early endosomal pathology, increased A beta PP alone has yet to be shown to be sufficient to drive early endosomal alterations in neurons. Comparing two A beta PP transgenic mouse models, one that contains the A beta PP Swedish K670N/M671L double mutation at the beta-cleavage site (APP23) and one that has the A beta PP London V717I mutation near the gamma-cleavage site (APPLd2), we show significantly altered early endosome morphology in fronto-parietal neurons as well as enlargement of early endosomes in basal forebrain cholinergic neurons of the medial septal nucleus in the APP23 model, which has the higher levels of A beta PP beta-C-terminal fragment (beta CTF) accumulation. Early endosomal changes correlate with a marked loss of the cholinergic population, which is consistent with the known dependence of the large projection cholinergic cells on endosome-mediated retrograde neurotrophic transport. Our findings support the idea that increased expression of A beta PP and A beta PP metabolites in neurons is sufficient to drive early endosomal abnormalities in vivo, and that disruption of the endocytic system is likely to contribute to basal forebrain cholinergic vulnerability.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据